KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Tax Provisions (2016 - 2025)

Historic Tax Provisions for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $526.0 million.

  • AbbVie's Tax Provisions rose 115.38% to $526.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$735.0 million, marking a year-over-year decrease of 13561.05%. This contributed to the annual value of -$570.0 million for FY2024, which is 14139.43% down from last year.
  • Latest data reveals that AbbVie reported Tax Provisions of $526.0 million as of Q3 2025, which was up 115.38% from $613.0 million recorded in Q2 2025.
  • In the past 5 years, AbbVie's Tax Provisions ranged from a high of $773.0 million in Q2 2024 and a low of -$2.2 billion during Q4 2024
  • Over the past 5 years, AbbVie's median Tax Provisions value was $394.0 million (recorded in 2021), while the average stood at $283.7 million.
  • In the last 5 years, AbbVie's Tax Provisions skyrocketed by 75652.17% in 2021 and then plummeted by 67886.6% in 2024.
  • AbbVie's Tax Provisions (Quarter) stood at $226.0 million in 2021, then soared by 118.14% to $493.0 million in 2022, then dropped by 21.3% to $388.0 million in 2023, then crashed by 678.87% to -$2.2 billion in 2024, then skyrocketed by 123.42% to $526.0 million in 2025.
  • Its Tax Provisions was $526.0 million in Q3 2025, compared to $613.0 million in Q2 2025 and $372.0 million in Q1 2025.